Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp. | Mutual Funds

Mutual Funds that own Blueprint Medicines Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Select Biotechnology Portfolio
1,709,411
3.9%
0
1.43%
07/31/2018
SPDR S&P Biotech ETF
1,097,362
2.5%
2,823
1.44%
09/06/2018
Vanguard Small Cap Index Fund
1,046,932
2.38%
12,752
0.08%
07/31/2018
Vanguard Total Stock Market Index Fund
1,045,233
2.38%
1,058
0.01%
07/31/2018
iShares Russell 2000 ETF
868,637
1.98%
-465
0.14%
09/06/2018
Oppenheimer Global Fund
852,303
1.94%
0
0.56%
03/31/2018
T Rowe Price Health Sciences Fund
848,322
1.93%
-57,529
0.51%
06/30/2018
Fidelity Select Health Care Portfolio
782,800
1.78%
1,700
0.79%
07/31/2018
Government Pension Fund - Global (The)
776,734
1.77%
751,734
0.01%
12/31/2017
T Rowe Price New Horizons Fund
675,103
1.54%
-161,583
0.21%
06/30/2018

About Blueprint Medicines

View Profile
Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.